Works by KLAMROTH, R.

Results: 37

Operation und Hämophilie : Kein Problem bei gutem interdisziplinären Management.

Published in:

2014

By:

Klamroth, R

Publication type:

journal article

Operation und Hämophilie.

Published in:

2014

By:

Klamroth, R.

Publication type:

Editorial

Neonatal bleeding in haemophilia: a European cohort study.

Published in:

British Journal of Haematology, 2012, v. 156, n. 3, p. 374, doi. 10.1111/j.1365-2141.2011.08967.x

By:

Richards, M.;
Lavigne Lissalde, G.;
Combescure, C.;
Batorova, A.;
Dolan, G.;
Fischer, K.;
Klamroth, R.;
Lambert, T.;
Lopez-Fernandez, M.;
Pérez, R.;
Rocino, A.;
Fijnvandraat, K.

Publication type:

Article

Abklärung einer erworbenen Blutungsneigung.

Published in:

Der Internist, 2014, v. 55, n. 5, p. 514, doi. 10.1007/s00108-013-3421-6

By:

Klamroth, R.

Publication type:

Article

Prospective evaluation of treatment regimens, efficacy and safety of a recombinant factor VIII concentrate in haemophilia A: the German EffeKt study.

Published in:

Haemophilia, 2016, v. 22, n. 5, p. 684, doi. 10.1111/hae.12941

By:

Klamroth, R.;
Miesbach, W.;
Staritz, P.

Publication type:

Article

Comparative pharmacokinetics of rVIII-SingleChain and octocog alfa (Advate®) in patients with severe haemophilia A.

Published in:

Haemophilia, 2016, v. 22, n. 5, p. 730, doi. 10.1111/hae.12985

By:

Klamroth, R.;
Simpson, M.;
Depka ‐ Prondzinski, M.;
Gill, J. C.;
Morfini, M.;
Powell, J. S.;
Santagostino, E.;
Davis, J.;
Huth ‐ Kühne, A.;
Leissinger, C.;
Neumeister, P.;
Bensen ‐ Kennedy, D.;
Feussner, A.;
Limsakun, T.;
Zhou, M.;
Veldman, A.;
St. Ledger, K.;
Blackman, N.;
Pabinger, I.

Publication type:

Article

How to compare cardiovascular disease and risk factors in elderly patients with haemophilia with the general population.

Published in:

Haemophilia, 2016, v. 22, n. 5, p. e406, doi. 10.1111/hae.13069

By:

Berger, K.;
Schopohl, D.;
Lowe, G.;
Holme, P. A.;
Tait, R. C.;
Combescure, C.;
Rauchensteiner, S.;
Klamroth, R.

Publication type:

Article

Immune tolerance induction in patients with haemophilia a and inhibitors: effectiveness and cost analysis in an European Cohort (The ITER Study).

Published in:

Haemophilia, 2016, v. 22, n. 1, p. 96, doi. 10.1111/hae.12780

By:

Rocino, A.;
Cortesi, P. A.;
Scalone, L.;
Mantovani, L. G.;
Crea, R.;
Gringeri, A.;
Altisent, C;
Astermark, J;
Diniz, MJ;
Fijnvandraat, K;
Klamroth, R;
Lambert, T;
Lavigne‐Lissalde, G;
Lopez‐Fernandez, MF;
Morfini, M

Publication type:

Article

How fit are children and adolescents with haemophilia in Germany? Results of a prospective study assessing the sport-specific motor performance by means of modern test procedures of sports science.

Published in:

Haemophilia, 2015, v. 21, n. 4, p. 523, doi. 10.1111/hae.12636

By:

Seuser, A.;
Boehm, P.;
Ochs, S.;
Trunz‐Carlisi, E.;
Halimeh, S.;
Klamroth, R.

Publication type:

Article

Spotlight on the human factor: building a foundation for the future of haemophilia A management.

Published in:

Haemophilia, 2015, v. 21, p. 1, doi. 10.1111/hae.12582

By:

Kessler, C.;
Oldenburg, J.;
Ettingshausen, C. Escuriola;
Tiede, A.;
Khair, K.;
Négrier, C.;
Klamroth, R.

Publication type:

Article

Management of atrial fibrillation in people with haemophilia – a consensus view by the ADVANCE Working Group.

Published in:

Haemophilia, 2014, v. 20, n. 6, p. e417, doi. 10.1111/hae.12525

By:

SCHUTGENS, R. E. G.;
KLAMROTH, R.;
PABINGER, I.;
DOLAN, G.

Publication type:

Article

Novel investigations on the protective role of the FVIII/ VWF complex in inhibitor development.

Published in:

Haemophilia, 2014, v. 20, n. 6, p. 2, doi. 10.1111/hae.12465

By:

Mannucci, P. M.;
Shi, Q.;
Bonanad, S.;
Klamroth, R.

Publication type:

Article

Atrial fibrillation in patients with haemophilia: a cross-sectional evaluation in Europe.

Published in:

Haemophilia, 2014, v. 20, n. 5, p. 682, doi. 10.1111/hae.12445

By:

SCHUTGENS, ROGER E. G.;
KLAMROTH, R.;
PABINGER, I .;
MALERBA, M.;
DOLAN, G.

Publication type:

Article

Results of the WIRK prospective, non-interventional observational study of recombinant activated factor VII ( rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disorders.

Published in:

Haemophilia, 2013, v. 19, n. 5, p. 679, doi. 10.1111/hae.12156

By:

Birschmann, I.;
Klamroth, R.;
Eichler, H.;
Schenk, J.;
Kirchmaier, C. M.;
Halimeh, S.

Publication type:

Article

Patient-reported outcomes of 182 adults with severe haemophilia in Germany comparing prophylactic vs. on-demand replacement therapy.

Published in:

Haemophilia, 2013, v. 19, n. 4, p. 558, doi. 10.1111/hae.12136

By:

Mondorf, W.;
Kalnins, W.;
Klamroth, R.

Publication type:

Article

Pain management in patients with haemophilia: a European survey.

Published in:

Haemophilia, 2012, v. 18, n. 5, p. 743, doi. 10.1111/j.1365-2516.2012.02808.x

By:

HOLSTEIN, K.;
KLAMROTH, R.;
RICHARDS, M.;
CARVALHO, M.;
PÉREZ-GARRIDO, R.;
GRINGERI, A.

Publication type:

Article

Management of bleeding disorders in adults.

Published in:

Haemophilia, 2012, v. 18, p. 24, doi. 10.1111/j.1365-2516.2012.02797.x

By:

PEYVANDI, F.;
KLAMROTH, R.;
CARCAO, M.;
FEDERICI, A. B.;
DI MINNO, G.;
JIMÉNEZ-YUSTE, V.;
RODRIGUEZ MERCHÁN, E. C.

Publication type:

Article

Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®) - an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A.

Published in:

Haemophilia, 2011, v. 17, n. 6, p. 854, doi. 10.1111/j.1365-2516.2011.02495.x

By:

MARTINOWITZ, U.;
BJERRE, J.;
BRAND, B.;
KLAMROTH, R.;
MISGAV, M.;
MORFINI, M.;
SANTAGOSTINO, E.;
TIEDE, A.;
VIUFF, D.

Publication type:

Article

Immune tolerance induction with a factor VIII concentrate containing von Willebrand factor (Haemoctin SDH®) in 14 patients with severe haemophilia A.

Published in:

Haemophilia, 2011, v. 17, n. 5, p. e837, doi. 10.1111/j.1365-2516.2011.02577.x

By:

BIDLINGMAIER, C.;
KURNIK, K.;
ESCURIOLA-ETTINGSHAUSEN, C.;
JAGER, R.;
KLAMROTH, R.;
MALE, C.;
MAROSI, A.;
NEMES, L.;
VON STACKELBERG, A.;
KREUZ, W.

Publication type:

Article

Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors.

Published in:

Haemophilia, 2011, v. 17, n. 4, p. 630, doi. 10.1111/j.1365-2516.2010.02467.x

By:

GRINGERI, A.;
FISCHER, K.;
KARAFOULIDOU, A.;
KLAMROTH, R.;
LÓPEZ-FERNÁNDEZ, M. F.;
MANCUSO, E.

Publication type:

Article

Management of acute haemarthrosis in haemophilia A without inhibitors: literature review, European survey and recommendations.

Published in:

Haemophilia, 2011, v. 17, n. 3, p. 383, doi. 10.1111/j.1365-2516.2010.02449.x

By:

Hermans, C.;
De Moerloose, P.;
Fisher, K.;
Holstein, K.;
Klamroth, R.;
Lambert, T.;
Lavigne-Lissalde, G.;
Perez, R.;
Richards, M.;
Dolan, G.

Publication type:

Article

The relative burden of haemophilia A and the impact of target joint development on health-related quality of life: results from the ADVATE Post-Authorization Safety Surveillance (PASS) study.

Published in:

Haemophilia, 2011, v. 17, n. 3, p. 412, doi. 10.1111/j.1365-2516.2010.02435.x

By:

Klamroth, R.;
Pollmann, H.;
Hermans, C.;
Faradji, A.;
Yarlas, A. S.;
Epstein, J. D;
Ewenstein, B. M

Publication type:

Article

Postmarketing surveillance study of KOGENATE® Bayer with Bio-Set® in patients with haemophilia A: evaluation of patients’ satisfaction after switch to the new reconstitution system.

Published in:

Haemophilia, 2010, v. 16, n. 1, p. 66, doi. 10.1111/j.1365-2516.2009.02113.x

By:

VIDOVIC, N.;
MUSSO, R.;
KLAMROTH, R.;
ENRIQUEZ, M. M.;
ACHILLES, K.

Publication type:

Article

Replacement therapy for invasive procedures in patients with haemophilia: literature review, European survey and recommendations.

Published in:

Haemophilia, 2009, v. 15, n. 3, p. 639, doi. 10.1111/j.1365-2516.2008.01950.x

By:

HERMANS, C.;
ALTISENT, C.;
BATOROVA, A.;
CHAMBOST, H.;
DE MOERLOOSE, P.;
KARAFOULIDOU, A.;
KLAMROTH, R.;
RICHARDS, M.;
WHITE, B.;
DOLAN, G.

Publication type:

Article

Challenges and controversies in haemophilia care in adulthood.

Published in:

Haemophilia, 2009, v. 15, p. 20, doi. 10.1111/j.1365-2516.2008.01949.x

By:

Dolan, G.;
Hermans, C.;
Klamroth, R.;
Madhok, R.;
Schutgens, R. E. G.;
Spengler, U.

Publication type:

Article

European curriculum for thrombosis and haemostasis.

Published in:

Haemophilia, 2009, v. 15, n. 1, p. 337, doi. 10.1111/j.1365-2516.2008.01836.x

By:

ASTERMARK, J.;
NEGRIER, C.;
HERMANS, C.;
HOLME, P. A.;
KLAMROTH, R.;
KOTSI, P.;
DE MOERLOOSE, P.;
PASI, J.;
ROCINO, A.;
VON DEPKA, M.;
WINDYGA, J.;
LUDLAM, C. A.

Publication type:

Article

Successful angiographic embolization of recurrent elbow and knee joint bleeds in seven patients with severe haemophilia.

Published in:

Haemophilia, 2009, v. 15, n. 1, p. 247, doi. 10.1111/j.1365-2516.2008.01842.x

By:

KLAMROTH, R.;
GOTTSTEIN, S.;
ESSERS, E.;
LANDGRAF, H.;
WILASCHEK, M.;
OLDENBURG, J.

Publication type:

Article

Cross-cultural development and psychometric evaluation of a patient-reported health-related quality of life questionnaire for adults with haemophilia.

Published in:

Haemophilia, 2008, v. 14, n. 5, p. 1023, doi. 10.1111/j.1365-2516.2008.01812.x

By:

RENTZ, A.;
FLOOD, E.;
ALTISENT, C.;
BULLINGER, M.;
KLAMROTH, R.;
GARRIDO, R. P.;
SCHARRER, I.;
SCHRAMM, W.;
GORINA, E.

Publication type:

Article

Should prophylaxis be used in adolescent and adult patients with severe haemophilia? An European survey of practice and outcome data.

Published in:

Haemophilia, 2007, v. 13, n. 5, p. 473, doi. 10.1111/j.1365-2516.2007.01478.x

By:

RICHARDS, M.;
ALTISENT, C.;
BATOROVA, A.;
CHAMBOST, H.;
DOLAN, G.;
DE MOERLOOSE, P.;
FRAGA, M.;
HERMANS, C.;
KARAFOULIDOU, A.;
KLAMROTH, R.;
LASSILA, R.;
ROTHSCHILD, C.

Publication type:

Article

Efficacy, safety and tolerability of recombinant factor VIII (REFACTO®) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria.

Published in:

Haemophilia, 2007, v. 13, n. 2, p. 131, doi. 10.1111/j.1365-2516.2006.01416.x

By:

POLLMANN, H.;
EXTERNEST, D.;
GANSER, A.;
EIFRIG, B.;
KREUZ, W.;
LENK, H.;
PABINGER, I.;
SCHRAMM, W.;
SCHWARZ, T. F.;
ZIMMERMANN, R.;
ZAVAZAVA, N.;
OLDENBURG, J.;
KLAMROTH, R.

Publication type:

Article

ReFacto®.

Published in:

Haemophilia, 2007, v. 13, n. 2, p. 124, doi. 10.1111/j.1365-2516.2006.01420.x

By:

DI PAOLA, J.;
SMITH, M. P.;
KLAMROTH, R.;
MANNUCCI, P. M.;
KOLLMER, C.;
FEINGOLD, J.;
KESSLER, C.;
POLLMANN, H.;
MORFINI, M.;
UDATA, C.;
ROTHSCHILD, C.;
HERMANS, C.;
JANCO, R.

Publication type:

Article

Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq® (human‐cl rhFVIII) in previously treated patients with severe haemophilia A.

Published in:

Haemophilia, 2018, v. 24, n. 4, p. 619, doi. 10.1111/hae.13493

By:

Dargaud, Y.;
Negrier, C.;
Rusen, L.;
Windyga, J.;
Georgiev, P.;
Bichler, J.;
Solomon, C.;
Knaub, S.;
Lissitchkov, T.;
Klamroth, R.

Publication type:

Article

Prospects for research in haemophilia with real‐world data—An analysis of German registry and secondary data.

Published in:

Haemophilia, 2018, v. 24, n. 4, p. 584, doi. 10.1111/hae.13443

By:

Schopohl, D.;
Bidlingmaier, C.;
Herzig, D.;
Klamroth, R.;
Kurnik, K.;
Rublee, D.;
Schramm, W.;
Schwarzkopf, L.;
Berger, K.

Publication type:

Article

PK-guided personalized prophylaxis with Nuwiq® (human-cl rh FVIII) in adults with severe haemophilia A.

Published in:

Haemophilia, 2017, v. 23, n. 5, p. 697, doi. 10.1111/hae.13251

By:

Lissitchkov, T.;
Rusen, L.;
Georgiev, P.;
Windyga, J.;
Klamroth, R.;
Gercheva, L.;
Nemes, L.;
Tiede, A.;
Bichler, J.;
Knaub, S.;
Belyanskaya, L.;
Walter, O.;
Pasi, K. J.

Publication type:

Article

Co-morbidities and bleeding in elderly patients with haemophilia-A survey of the German, Austrian and Swiss Society of Thrombosis and Haemostasis Research (GTH).

Published in:

Haemophilia, 2017, v. 23, n. 5, p. 721, doi. 10.1111/hae.13296

By:

Miesbach, W.;
Reitter‐Pfoertner, S.‐E.;
Klamroth, R.;
Langer, F.;
Wolf, H.‐H.;
Tiede, A.;
Siegmund, B.;
Scholz, U.;
Müller, P. R.;
Eichler, H.;
Pabinger, I.

Publication type:

Article

Outcome measures in European patients with haemophilia.

Published in:

Haemophilia, 2017, v. 23, n. 2, p. 222, doi. 10.1111/hae.13085

By:

Hermans, C.;
Klamroth, R.;
Richards, M.;
Moerloose, P.;
Garrido, R. P.;
Altisent, C.;
Astermark, J.;
Batorova, A.;
Carvalho, M.;
Dolan, G.;
Fijnvandraat, K.;
Holme, P.A.;
Holstein, K.;
Jimenez‐Yuste, V.;
Katsarou, O.;
Kavakli, K.;
Lambert, T.;
Lopéz, F.;
Pérez, R.;
Rocino, A.

Publication type:

Article

Low bleeding rates with increase or maintenance of physical activity in patients treated with recombinant factor VIII Fc fusion protein ( rFVIIIFc) in the A-LONG and Kids A- LONG Studies.

Published in:

Haemophilia, 2017, v. 23, n. 1, p. e39, doi. 10.1111/hae.13125

By:

Quon, D. V.;
Klamroth, R.;
Kulkarni, R.;
Shapiro, A. D.;
Baker, R. I.;
Castaman, G.;
Kerlin, B. A.;
Tsao, E.;
Allen, G.

Publication type:

Article

Works by KLAMROTH, R.

Operation und Hämophilie : Kein Problem bei gutem interdisziplinären Management.

Operation und Hämophilie.

Neonatal bleeding in haemophilia: a European cohort study.

Abklärung einer erworbenen Blutungsneigung.

Prospective evaluation of treatment regimens, efficacy and safety of a recombinant factor VIII concentrate in haemophilia A: the German EffeKt study.

Comparative pharmacokinetics of rVIII-SingleChain and octocog alfa (Advate<sup>®</sup>) in patients with severe haemophilia A.

How to compare cardiovascular disease and risk factors in elderly patients with haemophilia with the general population.

Immune tolerance induction in patients with haemophilia a and inhibitors: effectiveness and cost analysis in an European Cohort (The ITER Study).

How fit are children and adolescents with haemophilia in Germany? Results of a prospective study assessing the sport-specific motor performance by means of modern test procedures of sports science.

Spotlight on the human factor: building a foundation for the future of haemophilia A management.

Management of atrial fibrillation in people with haemophilia – a consensus view by the ADVANCE Working Group.

Novel investigations on the protective role of the FVIII/ VWF complex in inhibitor development.

Atrial fibrillation in patients with haemophilia: a cross-sectional evaluation in Europe.

Results of the WIRK prospective, non-interventional observational study of recombinant activated factor VII ( rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disorders.

Patient-reported outcomes of 182 adults with severe haemophilia in Germany comparing prophylactic vs. on-demand replacement therapy.

Pain management in patients with haemophilia: a European survey.

Management of bleeding disorders in adults.

Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE<sup>®</sup>) - an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A.

Immune tolerance induction with a factor VIII concentrate containing von Willebrand factor (Haemoctin SDH<sup>®</sup>) in 14 patients with severe haemophilia A.

Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors.

Management of acute haemarthrosis in haemophilia A without inhibitors: literature review, European survey and recommendations.

The relative burden of haemophilia A and the impact of target joint development on health-related quality of life: results from the ADVATE Post-Authorization Safety Surveillance (PASS) study.

Postmarketing surveillance study of KOGENATE<sup>®</sup> Bayer with Bio-Set<sup>®</sup> in patients with haemophilia A: evaluation of patients’ satisfaction after switch to the new reconstitution system.

Replacement therapy for invasive procedures in patients with haemophilia: literature review, European survey and recommendations.

Challenges and controversies in haemophilia care in adulthood.

European curriculum for thrombosis and haemostasis.

Successful angiographic embolization of recurrent elbow and knee joint bleeds in seven patients with severe haemophilia.

Cross-cultural development and psychometric evaluation of a patient-reported health-related quality of life questionnaire for adults with haemophilia.

Should prophylaxis be used in adolescent and adult patients with severe haemophilia? An European survey of practice and outcome data.

Efficacy, safety and tolerability of recombinant factor VIII (REFACTO<sup>®</sup>) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria.

ReFacto®.

Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq<sup>®</sup> (human‐cl rhFVIII) in previously treated patients with severe haemophilia A.

Prospects for research in haemophilia with real‐world data—An analysis of German registry and secondary data.

PK-guided personalized prophylaxis with Nuwiq<sup>®</sup> (human-cl rh FVIII) in adults with severe haemophilia A.

Co-morbidities and bleeding in elderly patients with haemophilia-A survey of the German, Austrian and Swiss Society of Thrombosis and Haemostasis Research (GTH).

Outcome measures in European patients with haemophilia.

Low bleeding rates with increase or maintenance of physical activity in patients treated with recombinant factor VIII Fc fusion protein ( rFVIIIFc) in the A-LONG and Kids A- LONG Studies.